New Wegovy Pill Offers Injectable Efficacy in Daily Dose

The U.S. Food and Drug Administration has approved a new daily oral pill for obesity, a significant step in the evolution of GLP-1 drugs. This medication, containing semaglutide, mirrors the efficacy of injectable treatments like Wegovy and Ozempic. Starting April 15, 2026, the 4mg dose will be priced at $199 per month, with higher 9mg and 25mg doses becoming available at $299 monthly from the same date. This approval, granted on December 22, positions Novo Nordisk to compete more effectively in the growing weight-loss market.

The introduction of an oral option addresses barriers faced by some patients, including the higher cost of injections, which can exceed $1,000 monthly, and a fear of needles. Experts believe this accessible pill format will increase the adoption of weight-loss medications globally, making effective chronic obesity management available to a wider population.

This oral semaglutide, sold under the brand name Wegovy, represents a breakthrough, offering injectable-like results in a daily pill. This innovation is anticipated to drive further growth for GLP-1 drugs and provides healthcare professionals with a valuable new tool in combating obesity, complementing existing injectable therapies.